ALTO NEUROSCIENCE, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2019-01-01
- Employees
- 63
- Market Cap
- $318.9M
ALTO-100 in Bipolar Disorder with Depression (BD-D)
- Conditions
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 200
- Registration Number
- NCT06656416
- Locations
- 🇺🇸
Site 6067, Lauderhill, Florida, United States
🇺🇸Site 6064, Peachtree Corners, Georgia, United States
🇺🇸Site 6151, Baltimore, Maryland, United States
Study of ALTO-101 in Patients With Schizophrenia
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 72
- Registration Number
- NCT06502964
- Locations
- 🇺🇸
Site 5083, Garden Grove, California, United States
🇺🇸Site 5062, Gaithersburg, Maryland, United States
🇺🇸Site 5055, Cedarhurst, New York, United States
PD, PK, and Safety of ALTO-203 in Patients With MDD
- Conditions
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 60
- Registration Number
- NCT06391593
- Locations
- 🇺🇸
Site 4058, Tucson, Arizona, United States
🇺🇸Site 4082, Oceanside, California, United States
🇺🇸Site 4059, Clermont, Florida, United States
Study of ALTO-300 in MDD
- First Posted Date
- 2023-06-28
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 200
- Registration Number
- NCT05922878
- Locations
- 🇺🇸
Site 220, West Palm Beach, Florida, United States
🇺🇸Site 119, Boise, Idaho, United States
🇺🇸Site 344, Las Vegas, Nevada, United States
Phase 2b Study of ALTO-100 in MDD
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 301
- Registration Number
- NCT05712187
- Locations
- 🇺🇸
Site 173, Huntsville, Alabama, United States
🇺🇸Site 118, Fresno, California, United States
🇺🇸Site 179, Rancho Cucamonga, California, United States
Pilot Decentralized Trial
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 21
- Registration Number
- NCT05419869
- Locations
- 🇺🇸
Site 156, Jackson, Mississippi, United States
🇺🇸Site 160, Coral Gables, Florida, United States
ALTO-300 in Depression (ALTO-300-004)
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 148
- Registration Number
- NCT05157945
- Locations
- 🇺🇸
Site 171, Jackson, Mississippi, United States
🇺🇸Cerebral - New York City, New York, New York, United States
🇺🇸Cerebral - Atlanta, Atlanta, Georgia, United States
ALTO-300 in Depression
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 91
- Registration Number
- NCT05118750
- Locations
- 🇺🇸
Site 102, Dallas, Texas, United States
🇺🇸Site 103, Sacramento, California, United States
🇺🇸Site 165, DeSoto, Texas, United States
ALTO-100 in MDD and/or PTSD
- Conditions
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Alto Neuroscience
- Target Recruit Count
- 245
- Registration Number
- NCT05117632
- Locations
- 🇺🇸
Site 139, Little Rock, Arkansas, United States
🇺🇸Site 150, Boca Raton, Florida, United States
🇺🇸Site 151, Baltimore, Maryland, United States
Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram
- First Posted Date
- 2020-05-14
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Alto Neuroscience
- Registration Number
- NCT04388202